Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

This study has been completed.
Information provided by National Heart, Lung, and Blood Institute (NHLBI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Cardiovascular Diseases
			Coronary Disease
			Diabetes Mellitus
			Heart Diseases
			Hypercholesterolemia
			Hypertension
			Myocardial Infarction
			Myocardial Ischemia
			Heart Failure
2		Additional conditions recognized in this trial
			Infarction
			Ischemia
3		More general conditions related to this trial
			Dyslipidemias
			Endocrine System Diseases
			Glucose Metabolism Disorders
			Hyperlipidemias
			Lipid Metabolism Disorders
			Metabolic Diseases
			Necrosis
			Pathologic Processes
			Vascular Diseases
4		Interventions listed in this trial
			Inhibitors, ACE
			amlodipine
			lisinopril
			doxazosin
			chlorthalidone
			pravastatin
			diet, fat-restricted
5		More general drug interventions related to this trial
			Angiotensin-Converting Enzyme Inhibitors
			Anticholesteremic Agents
			Antihypertensive Agents
			Antilipemic Agents
			Antimetabolites
			Calcium Channel Blockers
			Cardiotonic Agents
			Cardiovascular Agents
			Diuretics
			Enzyme Inhibitors
			Hydroxymethylglutaryl-CoA Reductase Inhibitors
			Membrane Transport Modulators
			Molecular Mechanisms of Pharmacological Action
			Natriuretic Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
			Protease Inhibitors
			Protective Agents
			Sodium Chloride Symporter Inhibitors
			Therapeutic Uses
			Vasodilator Agents
6		Sponsors listed in this trial
			National Heart, Lung, and Blood Institute (NHLBI)